P930038/S107: Angio Seal VIP Vascular Closure Device
FDA’s recorded scope: the addition of a new U.S. farm and a new USDA-registered abattoir for collagen
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 7 FDA records to the applicant name Terumo Medical Corporation. 3 entries are PMA supplements. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 5, 2025 to Aug 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NIP appears in 4 of the 7 linked filings. The collection spans 3 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P140002, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 950 Elkton Blvd., Elkton, MD, 21921. Recorded on P930038/S107, decision dated Aug 4, 2026.
Device, Hemostasis, Vascular; Stent, Iliac; Stent, Superficial Femoral Artery.
FDA’s recorded scope: the addition of a new U.S. farm and a new USDA-registered abattoir for collagen
FDA’s recorded scope: The Misago RX Self-expanding Peripheral Stent is indicated to improve the luminal diameter in patient with de novo, restenotic and/or occlusive atherosclerotic lesion(s) in the common and/or external iliac artery. The reference vessel diameters range from 4.0 mm to 9.0 mm and the lesion length is up to 120 mm.
FDA’s recorded scope: approval for an additional silicone oil manufacturer
FDA’s recorded scope: packaging material, performance testing, and label placement changes
FDA’s recorded scope: changes to the endotoxin test procedures and the addition of a lubricant to non-patient-contacting components
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
| Recall / product | Company | Classification | Report date | Source |
|---|---|---|---|---|
| Terumo Medical Corporation | Class II | Aug 19, 2026 | FDA |
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Source updated Nov 11, 2026. Retrieved Nov 21, 2026.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.